Anelia V. Delcheva

Anelia V. Delcheva

Morrison & Foerster LLP

Contact  |  View Bio  |  RSS

Latest Posts › Prescription Drugs

Share:

MoFo BioMeter - Vol. 2, Issue 4, November 2013 - Q3 BioMeter Shows Strong Early Stage Deals

The average BioMeter value in the third quarter of 2013 was $30.4 million, an increase from the $22.2 million value in the second quarter. Like last quarter, Phase 1 and Phase 2 transactions showed very strong results, with...more

11/26/2013 - Biotechnology Pharmaceutical Prescription Drugs

MoFo BioMeter - Volume 2, Issue 2: May 2013 - Flat BioMeter Value and Decline in Deal Volume are Hallmarks of Q1

The Morrison & Foerster BioMeter for the first quarter of 2013 shows a flat quarter for BioMeter value and a decline in dealmaking activity. A small number of large deals dominate an otherwise quiet quarter. In the...more

5/31/2013 - Biotechnology OTC Pharmaceutical Prescription Drugs Valuation

2 Results
|
View per page
Page: of 1